x
Filter:
Filters applied
- Coronavirus (COVID-19) Collection
- Rapid CommunicationRemove Rapid Communication filter
Publication Date
Please choose a date range between 2020 and 2022.
Author
- He, Daihai6
- Yang, Lin4
- Alcoba-Florez, Julia3
- Cao, Peihua3
- Ciuffreda, Laura3
- Corral, Octavio3
- Flores, Carlos3
- Gil-Campesino, Helena3
- González-Montelongo, Rafaela3
- Lippi, Giuseppe3
- Lou, Yijun3
- Barreiro, Pablo2
- Bordi, Licia2
- Chaudet, Hervé2
- Colson, Philippe2
- Dugas, Martin2
- Ergönül, Önder2
- Furuse, Yuki2
- Giraud-Gatineau, Audrey2
- Gómez-Gallego, Felix2
- Huerta, Miguel2
- Lin, Qianying2
- Mattar, Salim2
- Mazzone, Antonino2
- Mendoza-Cano, Oliver2
Coronavirus (COVID-19) Collection
212 Results
- Short CommunicationOpen Access
Time from last immunity event against infection during Omicron-dominant period in Malaysia
International Journal of Infectious DiseasesVol. 128p98–101Published online: December 26, 2022- Su Lan Yang
- Adiratna Mat Ripen
- Jen Ven Lee
- Karina Koh
- Chia How Yen
- Avinash Kumar Chand
- and others
Cited in Scopus: 0The SARS-CoV-2 Omicron variant (B.1.1.529) and its prominent sublineages continue to be the dominant strains (>98%) circulating globally since February 2022 [1–3]. The spike mutations of Omicron resulted in higher viral transmissibility and capability to escape neutralizing antibodies from vaccinated sera [4]. Immune evasion is evident because a higher number of breakthrough and reinfection cases were observed during the Omicron-dominant period [5,6]. Symptomatic COVID-19 cases increased as studies found moderate booster effectiveness against Omicron infection, whereas the effectiveness against severe outcomes was largely preserved [7,8]. - Rapid CommunicationOpen Access
Post-acute symptoms 3-15 months after COVID-19 among unvaccinated and vaccinated individuals with a breakthrough infection
International Journal of Infectious DiseasesVol. 126p10–13Published online: November 11, 2022- Sonja H. Brunvoll
- Anders B. Nygaard
- Morten W. Fagerland
- Petter Holland
- Merete Ellingjord-Dale
- John Arne Dahl
- and others
Cited in Scopus: 1Vaccination represents the most important strategy to prevent infection, severe complications, and death caused by SARS-CoV-2 (Feikin et al., 2022). SARS-CoV-2 vaccination may also reduce the risk of post-acute sequelae of SARS-CoV-2 infection (PASC) (Antonelli et al., 2022; Azzolini et al., 2022; Kuodi et al., 2022), but conflicting results have been presented (Taquet et al., 2022). We aimed to describe self-reported PASC symptoms, including memory and concentration problems, changes in smell and taste, fatigue, and dyspnea, persisting 3-15 months after a positive test in SARS-CoV-2 unvaccinated and vaccinated participants with a breakthrough infection. - Rapid CommunicationOpen Access
Clinical outcomes associated with Mu variant infection during the third epidemic peak of COVID-19 in Colombia
International Journal of Infectious DiseasesVol. 125p149–152Published online: November 1, 2022- Diego A. Álvarez-Díaz
- Hector A. Ruiz-Moreno
- Silvana Zapata-Bedoya
- Carlos Franco-Muñoz
- Katherine Laiton-Donato
- Carolina Ferro
- and others
Cited in Scopus: 0By July 2022, four COVID-19 epidemic peaks and 210 lineages have been registered in Colombia, including several variants of interest and concern (INS, 2022). However, a higher number of cases and deaths occurred during the third epidemic peak, when the B.1.621 (Mu) variant was associated with 50% of the cases in the country (Álvarez-Díaz et al., 2022a). Although several factors in the clinical history of patients with COVID-19 have been associated with a severe or fatal outcome, including comorbidities, age, and smoking history (Zhang et al. - Short communicationOpen Access
Effectiveness of messenger RNA vaccines against infection with SARS-CoV-2 during the periods of Delta and Omicron variant predominance in Japan: the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study
International Journal of Infectious DiseasesVol. 125p58–60Published online: October 8, 2022- Wataru Mimura
- Chieko Ishiguro
- Megumi Maeda
- Fumiko Murata
- Haruhisa Fukuda
Cited in Scopus: 0Vaccination against infection with SARS-CoV-2 in the general population of Japan began on April 12, 2021, and booster vaccination (the third dose) began on December 1, 2021. The Alpha (B.1.1.7) variant was gradually replaced by the Delta (B.1.617.2) variant beginning in June 2021, and the Delta variant accounted for approximately 80% of infections in Japan in August 2021 (National Institute of Infectious Diseases, 2021). The Delta variant predominated until the Omicron (B.1.1.529) variant surged in January 2022 (National Institute of Infectious Diseases, 2022; Ode et al. - Short CommunicationOpen Access
Critical pediatric neurological illness associated with COVID-19 (Omicron BA.2.3.7 variant) infection in Taiwan: immunological assessment and viral genome analysis in tertiary medical center
International Journal of Infectious DiseasesVol. 124p45–48Published online: September 7, 2022- Chi-Sheng Chen
- Chia-Ning Chang
- Chih-Fen Hu
- Ming-Jr Jian
- Hsing-Yi Chung
- Chih-Kai Chang
- and others
Cited in Scopus: 3Since the COVID-19 pandemic outbreak, people all around the world have continued to fight it (Jian et al., 2022). However, as the virus evolves, more variants of concern have been reported (Chung et al., 2022). Patients with COVID-19 infection have also experienced neurological symptoms during the course of the infection (Nordvig et al., 2021). However, severe neurological complications have tended to be more common in children recently (Dilber et al., 2021; Valderas et al., 2022). - Short CommunicationOpen Access
Monitoring of SARS-CoV-2 circulation using saliva testing in school children in Rome, Italy
International Journal of Infectious DiseasesVol. 124p11–13Published online: September 7, 2022- Giuseppe Sberna
- Rosanna Guarini
- Francesco Vaia
- Fabrizio Maggi
- Licia Bordi
- on behalf of Covid-Saliva Laboratory team
Cited in Scopus: 0Since October 2020, the identification of suspected cases and contact tracing in the Lazio region have been supported by active surveillance initiatives in schools through antigen tests performed mainly on saliva (Bordi et al., 2021; Iwasaki et al., 2020). For the school year 2021-2022, the National Plan implemented the “Plan for monitoring of the circulation of SARS-CoV-2 in primary and lower secondary schools”. The Laboratory of Virology of the National Institute for Infectious Diseases “L. Spallanzani” was involved in the screening of saliva samples collected from students belonging to the local surveillance unit (ASL) RM3 of Rome. - Short CommunicationOpen Access
Validation of the NeuMoDx™ SARS-CoV-2 assay with COPAN eNAT® and E&O Viral PCR Sample Solution collection media types in comparison with other validated SARS-CoV-2 RNA assays
International Journal of Infectious DiseasesVol. 122p864–866Published online: July 15, 2022- Daniel Baird
- Alana Muir
- Lisa Logan
- Mairiead MacLennan
Cited in Scopus: 0Reverse transcriptase polymerase chain reaction (RT-PCR) assays for the detection of SARS-CoV-2 RNA are the gold standard for diagnosis because of their high sensitivity and specificity (Park et al., 2020). Assay validation during the pandemic was challenging because of the need for rapid implementation of novel tests (Vandenberg et al., 2021). - Short CommunicationOpen Access
Admissions to a large tertiary care hospital and Omicron BA.1 and BA.2 SARS-CoV-2 polymerase chain reaction positivity: primary, contributing, or incidental COVID-19
International Journal of Infectious DiseasesVol. 122p665–668Published online: July 12, 2022- Anne F. Voor in ’t holt
- Cynthia P. Haanappel
- Janette Rahamat–Langendoen
- Richard Molenkamp
- Els van Nood
- Leon M. van den Toorn
- and others
Cited in Scopus: 3Monitoring national hospitalization rates for COVID-19 has been essential throughout the pandemic to guide public health decision-making and to evaluate vaccine efficacy. However, with the rapid worldwide spread of the SARS-CoV-2 Omicron variant of concern (associated with a decreased severity) and increasing immunity against SARS-CoV-2, interpreting the true impact of these hospitalization rates has been complicated (Viana et al., 2022; World Health Organization, 2021). - Short CommunicationOpen Access
Assessing the proportion of the Danish population at risk of clinically significant drug-drug interactions with new oral antivirals for early treatment of COVID-19
International Journal of Infectious DiseasesVol. 122p599–601Published online: July 6, 2022- Carsten Schade Larsen
Cited in Scopus: 2Infection with SARS-CoV-2 usually causes mild to moderate respiratory disease. However, elderly patients and those with underlying chronic medical conditions are at high risk of progressing to severe COVID-19 (Ko et al., 2021; Thakur et al., 2021). - Short CommunicationOpen Access
Is a single dose of ChAdOx1 nCoV‐19 vaccine (AZD1222) enough for people with prior SARS‐CoV‐2 infection or baseline seropositive status?
International Journal of Infectious DiseasesVol. 123p143–144Published online: July 3, 2022- Vikas Deswal
- Rashmi Phogat
- Pooja Sharma
- Sushila Kataria
- Arvinder Soin
Cited in Scopus: 1At present, the most effective strategy against the COVID-19 pandemic is to reach a point where the majority of the population is immune, either from natural infection or vaccination. Complete vaccination is a herculean task in a populous country such as India due to limited vaccine availability. Two doses are needed for most vaccines, where the second dose acts as a booster. Alternatively, SARS-CoV-2 infection could act as a natural vaccine (Prime dose) after which, one dose could act as a booster dose and may give adequate immunity. - Short CommunicationsOpen Access
A metropolitan-scale, three-dimensional agent-based model to assess the effectiveness of the COVID-19 Omicron wave interventions in a hyperdense city: a case study of Hong Kong
International Journal of Infectious DiseasesVol. 122p534–536Published online: July 2, 2022- Keumseok Koh
- Ka Chung Tang
- Kay Axhausen
- Becky P.Y. Loo
Cited in Scopus: 1Despite its stringent containment measures, Hong Kong has experienced a most challenging COVID-19 wave due to the Omicron variant (Mallapaty, 2022). Implementing a citywide ‘compulsory universal testing’ (CUT) and a citywide lockdown was a subject of debate in March 2022 (South China Morning Post, 2022). - Short CommunicationOpen Access
Humoral and adaptive immune responses to the SARS-CoV-2 vaccine
International Journal of Infectious DiseasesVol. 122p412–414Published online: June 21, 2022- Roberta Rizzo
- Daria Bortolotti
- Luca Morandi
- Sabrina Rizzo
- Giovanna Schiuma
- Silvia Beltrami
- and others
Cited in Scopus: 0Vaccines against SARS-CoV-2 prevent infection and adverse outcomes from SARS-CoV-2 (Olliaro et al., 2021). Elicitation of high affinity and durable protective antibody responses is a hallmark of a successful humoral immune response to vaccination (Turner et al., 2021). Antibody responses decline sharply at six months, particularly after SARS-CoV-2 mRNA vaccines (Collier et al., 2021). A recent study showed that after 20 weeks or more, the vaccination with two doses is effective against COVID-19–related hospitalization and death with a waning of the clinical protection in older adults and fragile/co-morbid patients (Andrews et al., 2022). - Short CommunicationOpen Access
SARS-CoV-2 intra-host evolution during prolonged infection in an immunocompromised patient
International Journal of Infectious DiseasesVol. 122p444–448Published online: June 17, 2022- Erika Giorgia Quaranta
- Alice Fusaro
- Edoardo Giussani
- Valeria D'Amico
- Maria Varotto
- Matteo Pagliari
- and others
Cited in Scopus: 3During the SARS-CoV-2 pandemic, several cases of prolonged infections were reported in immunosuppressed patients (Dolan et al., 2021). Most of these cases revealed an intra-host viral evolution, which allows the virus to accumulate mutations faster than during normal inter-host transmission (Avanzato et al., 2020; Leung et al., 2022). During these prolonged infections, SARS-CoV-2 can acquire mutations at key epitopes in the Spike (S) protein, potentially affecting virus replication, infectivity, and antigenicity, which are common to the variants of concern (VOCs) (European Centre for Disease Prevention and Control, 2022). - Rapid CommunicationOpen Access
Invasive Pneumococcal Disease diminish during the onset of COVID-19 in Japan between 2019 and 2022
International Journal of Infectious DiseasesVol. 122p307–309Published online: June 3, 2022- Thanawat Khongyot
- Taeko Moriyasu
Cited in Scopus: 2Streptococcus pneumoniae can cause invasive pneumococcal disease (IPD) at a patient's sterile site, including the cerebrospinal fluid and blood, and commonly presents with septicemia, meningitis, and pneumonia (Dowell et al., 2003). In Japan, both children and older individuals receive public support for pneumococcal vaccination. Pneumococcal vaccine coverage has been increased since the launch of the vaccine program (Naito et al., 2020). - Rapid CommunicationOpen Access
Risk Factors Associated with Severe/Critical COVID-19 in People Living with HIV-1
International Journal of Infectious DiseasesVol. 122p152–154Published online: May 29, 2022- Antoine Bachelard
- Aurelie Sautereau
- Marc Digumber
- Valentina Isernia
- Bao Phung
- Anne-Claire Lehur
- and others
Cited in Scopus: 3Risk factors have been described as associated with severe forms of COVID-19 (Zhang et al., 2020). Persons living with HIV-1 (PLWH1) often carry such comorbidities. As shown by Bhaskaran et al (2021), PLWH1 are at a greater risk of developing a severe form of COVID-19. Our objective was to determine the characteristics associated with the development of a severe or critical form of COVID-19 in a cohort of PLWH1 who were followed up at the Bichat-Claude Bernard University Hospital in Paris, France. - Short CommunicationOpen Access
Real-world effectiveness of COVID-19 vaccination among children in Italy
International Journal of Infectious DiseasesVol. 122p70–71Published online: May 19, 2022- Camilla Mattiuzzi
- Giuseppe Lippi
Cited in Scopus: 3In this study, we analyzed the clinical efficacy of mRNA-based COVID-19 vaccines among Italian children aged 5 to 11 years, using data published by the National Institute of Health. Vaccination status was associated with a reduced risk of COVID-19–related hospitalizations and intensive care unit (ICU) admissions, which were 41% (odds ratio, 0.59; 95% confidence interval [CI], 0.46-0.77) and 68% (odds ratio, 0.32; 95% CI, 0.04-2.63), respectively, lower in children who completed the vaccination cycle <120 days than in the unvaccinated matched population. - Short communicationsOpen Access
High population burden of Omicron variant (B.1.1.529) is associated with the emergence of severe hepatitis of unknown etiology in children
International Journal of Infectious DiseasesVol. 122p30–32Published online: May 12, 2022- Hiroshi Nishiura
- Sung-mok Jung
- Katsuma Hayashi
Cited in Scopus: 16The Omicron variant (B.1.1.529) emerged in late 2021, causing a widespread epidemic across the world, including in countries that had taken containment strategy with “zero-COVID” policy (Petersen et al., 2022). In industrialized countries that have experienced major extensive epidemics of Omicron, substantial fraction of the population was exposed, including children. For instance, a published seroepidemiological study in the United States indicated that approximately 75% of children have been infected by the end of February 2022 (Clarke et al., 2022). - Short CommunicationOpen Access
Early remdesivir to prevent severe COVID-19 in recipients of solid organ transplant: a real-life study from Northern Italy
International Journal of Infectious DiseasesVol. 121p157–160Published online: May 6, 2022- Marta Colaneri
- Nicolò Amarasinghe
- Leonardo Rezzonico
- Teresa Chiara Pieri
- Emilio Segalini
- Margherita Sambo
- and others
Cited in Scopus: 7COVID-19 remains a life-threatening disease for recipients of solid organ transplant (SOT) who might not mount an adequate protective response to vaccination (Sait et al., 2022). With this in mind, it is extremely relevant to deal with the recent SARS-CoV-2 infection in these patients, starting with treatments which may prevent the COVID-19 progression (National Institutes of Health, 2022b). - Short CommunicationOpen Access
Real-world effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection among adolescents (12 to 17-year-olds) in Malaysia
International Journal of Infectious DiseasesVol. 121p55–57Published online: April 29, 2022- Masliyana Husin
- Peter Seah Keng Tok
- Jing Lian Suah
- Thevesh Thevananthan
- Boon Hwa Tng
- Kalaiarasu M. Peariasamy
- and others
Cited in Scopus: 4Vaccinating against the SARS-CoV-2 virus to achieve high population immunity is essential to realise health and socio-economic goals driving the global COVID-19 vaccination strategy (World Health Organization. Strategy to achieve global COVID-19 vaccination by mid-2022.). In Malaysia, the national vaccination programme for COVID-19 began in February 2021 using a diverse platform of vaccines (Suah et al., 2021). It was demonstrated that they offer considerable protection, particularly against severe outcomes (Suah et al., 2022, 2021). - Short CommunicationOpen Access
Colorimetric detection of SARS-CoV-2 by uracil-DNA glycosylase (UDG) reverse transcription loop-mediated isothermal amplification (RT-LAMP)
International Journal of Infectious DiseasesVol. 120p132–134Published online: April 23, 2022- Meng Yee Lai
- Fatma Diyana Mohd Bukhari
- Nur Zulaikha Zulkefli
- Ilyiana Ismail
- Nur Izati Mustapa
- Tuan Suhaila Tuan Soh
- and others
Cited in Scopus: 2It has been more than two years since the beginning of the SARS-CoV-2 pandemic. Rapid diagnostic methods such as reverse transcription loop-mediated isothermal amplification (RT-LAMP) (Notomi et al., 2000) are critically important to minimize the spread of the illness and protect the public. - Short CommunicationOpen Access
SARS-COV-2 IgG positivity in vaccinated and non-vaccinated Chilean children: a national cross-sectional study in schools
International Journal of Infectious DiseasesVol. 121p89–91Published online: April 23, 2022- Juan P. Torres
- Denis Sauré
- Leonardo J. Basso
- Marcela Zuñiga
- Andre Cazor
- Miguel O'Ryan
Cited in Scopus: 1COVID-19 vaccination of children is gaining global support (Committee on Infectious Diseases, 2022), and data on immunogenicity and efficacy/effectiveness are increasing (Walter et al., 2022; Frenck et al., 2021; Han et al., 2021). Chile has rapidly advanced in a national vaccination campaign for children: as of February 17, 2022, 79% of children aged 3–17 years have been fully vaccinated (Ministerio de Salud Chile, 2022). Children aged 12–17 years have been vaccinated since June 22, 2021, with the mRNA Pfizer/BioNTech vaccine, followed weeks later by children aged 6–11 years, who received the inactivated Sinovac vaccine. - Short communicationOpen Access
COVID-19 vaccines provide better protection against related pneumonia than previous symptomatic infection
International Journal of Infectious DiseasesVol. 120p142–145Published online: April 23, 2022- Efrén Murillo-Zamora
- Xóchitl Trujillo
- Miguel Huerta
- Mónica Ríos-Silva
- José Guzmán-Esquivel
- Verónica Benites-Godínez
- and others
Cited in Scopus: 1The burden of the COVID-19 pandemic in Mexico has been high and by mid-October 2021, more than 3.7 million laboratory-confirmed cases have been registered, with more than 280 thousand deaths. - Short CommunicationOpen Access
Using SARS-CoV-2 anti-S IgG levels as a marker of previous infection: example from an Israeli healthcare worker cohort.
International Journal of Infectious DiseasesVol. 120p22–24Published online: April 9, 2022- Kamal Abu Jabal
- Michael Edelstein
Cited in Scopus: 2Detecting current or previous SARS-CoV-2 infection is an essential component of pandemic management. Beyond case ascertainment and contact tracing, previous infection knowledge determines reinfection risk, the number and timing of vaccine doses required (Abu Jabal et al., 2021; Hansen et al., 2021), and can serve as evidence to attribute postviral symptoms to infection. Determining acute infection status relies on detecting viral DNA through polymerase chain reaction (PCR) or viral proteins through rapid antigen testing which has limited sensitivity (Wölfl-Duchek et al., 2022). - Short CommunicationOpen Access
Effect of a two-dose vs three-dose vaccine strategy in residential colleges using an empirical proximity network
International Journal of Infectious DiseasesVol. 119p210–213Published online: April 7, 2022- Hali L. Hambridge
- Rebecca Kahn
- Jukka-Pekka Onnela
Cited in Scopus: 0When SARS-CoV-2 escalated to a pandemic in early 2020, universities and colleges were forced to pivot to virtual instruction. As of fall 2021, many institutions of higher education had reopened, adopting and often mandating mitigation measures like indoor masking, social distancing, regular testing, and vaccination. However, the emergence of the Omicron B.1.1.529 variant in November 2021 disrupted this new routine. The Omicron variant has been shown to be highly transmissible, with researchers estimating the effective reproduction number of Omicron as 3.19 times higher than that of the Delta strain (Ito et al., 2021). - Short CommunicationsOpen Access
Diagnostic accuracy of SARS-CoV-2 saliva antigen testing in a real-life clinical setting
International Journal of Infectious DiseasesVol. 119p38–40Published online: March 29, 2022- Sabrina Jegerlehner
- Franziska Suter-Riniker
- Philipp Jent
- Pascal Bittel
- Michael Nagler
Cited in Scopus: 2Testing for SARS-CoV-2 is an essential component of the pandemic response. Rapid antigen tests using saliva were suggested as a quick, simple, comfortable, and non-invasive testing method. Only minimal training is required to conduct these tests, facilitating application in various primary care and even self-testing settings. Several studies suggested that saliva antigen tests might have an adequate performance in diagnosing SARS-CoV-2 infection (Mattiuzzi et al., 2020). However, little is known about the diagnostic accuracy in real-life clinical settings, which might be significantly different from that reported in manufacturer data (Jegerlehner et al., 2021, Mattiuzzi et al., 2020).